2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Paolo A. Ascierto
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Paolo A. Ascierto
Login to view comments.
Click here to Login